| 000 | 01804 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514020739.0 | ||
| 264 | 0 | _c20020213 | |
| 008 | 200202s 0 0 eng d | ||
| 022 | _a0885-6230 | ||
| 024 | 7 |
_a10.1002/1099-1166(200112)16:1+<::aid-gps571>3.0.co;2-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKennedy, J S | |
| 245 | 0 | 0 |
_aA current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. _h[electronic resource] |
| 260 |
_bInternational journal of geriatric psychiatry _cDec 2001 |
||
| 300 |
_aS33-61 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAdverse Drug Reaction Reporting Systems |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAlzheimer Disease _xdrug therapy |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBenzodiazepines |
| 650 | 0 | 4 |
_aBrain _xdrug effects |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeurologic Examination _xdrug effects |
| 650 | 0 | 4 | _aOlanzapine |
| 650 | 0 | 4 |
_aPirenzepine _xadverse effects |
| 650 | 0 | 4 |
_aReceptors, Neurotransmitter _xdrug effects |
| 700 | 1 | _aBymaster, F P | |
| 700 | 1 | _aSchuh, L | |
| 700 | 1 | _aCalligaro, D O | |
| 700 | 1 | _aNomikos, G | |
| 700 | 1 | _aFelder, C C | |
| 700 | 1 | _aBernauer, M | |
| 700 | 1 | _aKinon, B J | |
| 700 | 1 | _aBaker, R W | |
| 700 | 1 | _aHay, D | |
| 700 | 1 | _aRoth, H J | |
| 700 | 1 | _aDossenbach, M | |
| 700 | 1 | _aKaiser, C | |
| 700 | 1 | _aBeasley, C M | |
| 700 | 1 | _aHolcombe, J H | |
| 700 | 1 | _aEffron, M B | |
| 700 | 1 | _aBreier, A | |
| 773 | 0 |
_tInternational journal of geriatric psychiatry _gvol. 16 Suppl 1 _gp. S33-61 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/1099-1166(200112)16:1+<::aid-gps571>3.0.co;2-5 _zAvailable from publisher's website |
| 999 |
_c11661560 _d11661560 |
||